NASDAQ:IMMU Immunomedics (IMMU) Stock Price, News & Analysis → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Free IMMU Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$87.86▼$87.8650-Day Range$85.08▼$87.8652-Week Range$8.80▼$87.93VolumeN/AAverage Volume4.01 million shsMarket Capitalization$20.31 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Immunomedics alerts: Email Address Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About Immunomedics Stock (NASDAQ:IMMU)Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast cancer. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140 for treatment of hematologic malignancies; and IMMU-130 to treat Colorectal cancer. Its other product candidates includes epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with GBG Forschungs GmbH to develop sacituzumab govitecan for the treatment of breast cancer; and clinical collaboration with F. Hoffman-La Roche Ltd to treat patients with metastatic or inoperable locally advanced TNBC versus atezolizumab plus nab-paclitaxel as standard of care. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. As of October 23, 2020, Immunomedics, Inc. operates as a subsidiary of Gilead Sciences, Inc.Read More Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" IMMU Stock News HeadlinesApril 19, 2024 | markets.businessinsider.comThe Analyst Verdict: Gilead Sciences In The Eyes Of 12 ExpertsApril 18, 2024 | benzinga.comWhat the Options Market Tells Us About Gilead SciencesApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 15, 2024 | finance.yahoo.comNorthStar Appoints Peter Pfreundschuh to Board of ManagersMarch 6, 2024 | finance.yahoo.comGilead bets on ‘trispecifics’ in latest cancer drug dealFebruary 29, 2024 | finance.yahoo.comAbingworth invests in Trodelvy development in deal with GileadFebruary 13, 2024 | msn.comGilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to PipelineFebruary 12, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead: Maintaining Our $97 Fair Value Estimate as CymaBay Acquisition Looks Like a Good FitApril 23, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… February 12, 2024 | finance.yahoo.comGilead to buy CymaBay in $4.3B deal for liver disease drugFebruary 7, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead Earnings: Maintaining $97 Fair Value Estimate as HIV and Oncology Catalysts ApproachJanuary 22, 2024 | finance.yahoo.comGilead Sciences, Inc.: Gilead: Trodelvy Lung Cancer Data Disappoints, but No Changes to Our Fair Value EstimateJanuary 16, 2024 | finance.yahoo.comArvinas Appoints Jared Freedberg as General CounselJanuary 9, 2024 | finance.yahoo.comNeuroTrauma Sciences Appoints William Fricker, CPA, MBA, as Chief Financial OfficerNovember 15, 2023 | benzinga.comGilead Sciences's Options: A Look at What the Big Money is ThinkingNovember 9, 2023 | benzinga.comA Closer Look at Gilead Sciences's Options Market DynamicsNovember 8, 2023 | finance.yahoo.comGilead Sciences, Inc.: Gilead Earnings: Maintaining Our $97 FVE Following In-Line HIV and Oncology PerformanceNovember 6, 2023 | bizjournals.comGilead sues former CFO of Immunomedics to claw back $4 millionNovember 6, 2023 | bizjournals.comDaily Digest: Slack CEO departs; Big East Bay battery factory opensOctober 29, 2023 | realmoney.thestreet.comSpate of Deal News Juices Start of This Week's TradingSeptember 14, 2023 | finance.yahoo.comUnraveling Gilead Sciences Inc's Dividend Performance and SustainabilityAugust 24, 2023 | uk.finance.yahoo.comAntibody Drug Conjugate (ADC) Markets, 2035August 13, 2023 | morningstar.com8 Undervalued Quality Healthcare StocksAugust 4, 2023 | finance.yahoo.comGilead Sciences, Inc.: Gilead's HIV Dominance and Growing Oncology Portfolio Support a Wide MoatJuly 19, 2023 | thestreet.comImmunomedics, Seattle Genetics Lead Biotech Movers on Deal NewsJuly 11, 2023 | finance.yahoo.comLooking For Attractive Uncorrelated Returns in a Highly Uncertain Market? Consider Merger ArbitrageJune 22, 2023 | marketwatch.comThe global Cell therapy Processing market Size during the period of 2023 to 2030 is expected grow at CAGR of 9.1%See More Headlines Receive IMMU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunomedics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2020Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic Substances Sub-IndustryBiotechnology Current SymbolNASDAQ:IMMU CUSIP45290710 CIK722830 Webwww.immunomedics.com Phone973-605-8200FaxN/AEmployees366Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-357,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-132.40% Return on Assets-51.32% Debt Debt-to-Equity RatioN/A Current Ratio12.84 Quick Ratio12.58 Sales & Book Value Annual Sales$290,000.00 Price / Sales70,028.66 Cash FlowN/A Price / Cash FlowN/A Book Value$1.38 per share Price / Book63.67Miscellaneous Outstanding Shares231,144,000Free FloatN/AMarket Cap$20.31 billion OptionableOptionable Beta2.90 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Behzad Aghazadeh Ph.D. (Age 49)Exec. Chairman Comp: $147.53kMr. Usama Malik (Age 45)CFO & Chief Bus. Officer Comp: $533.39kMr. Brendan P. Delaney (Age 45)Chief Commercial Officer Comp: $527.63kMr. Bryan Ball (Age 50)Chief Quality Officer Comp: $646.48kMr. William Fricker (Age 55)Principal Accounting Officer, Exec. Director & Corp. Controller Ms. Phyllis ParkerDirector of Admin.Dr. Chau ChengSr. Director of Investor RelationsMr. Jared Freedberg (Age 52)Gen. Counsel & Corp. Sec. Mr. Kurt J. W. Andrews (Age 51)Chief HR Officer Dr. Loretta M. Itri (Age 70)Chief Medical Officer More ExecutivesKey CompetitorsLantheusNASDAQ:LNTHQuidelOrthoNASDAQ:QDELNeogenNASDAQ:NEOGCelldex TherapeuticsNASDAQ:CLDXIntellia TherapeuticsNASDAQ:NTLAView All Competitors Should I Buy Immunomedics Stock? IMMU Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Immunomedics, Inc.: Immunomedics, Inc. has a strong pipeline of monoclonal antibody-based products, including sacituzumab govitecan for metastatic triple-negative breast cancer, which has shown promising results in clinical trials. The company's collaboration with Gilead Sciences, Inc. provides financial stability and potential for further growth and development. Immunomedics, Inc. has a focus on commercializing innovative treatments for cancer, tapping into a high-demand market with significant growth potential. Recent partnerships and collaborations with industry leaders like AstraZeneca, MedImmune, and F. Hoffman-La Roche Ltd. indicate strong industry recognition and support for the company's products. With the acquisition by Gilead Sciences, Inc., Immunomedics, Inc. now has access to additional resources and expertise to accelerate product development and commercialization. Cons Investors should be bearish about investing in Immunomedics, Inc. for these reasons: Market volatility and regulatory challenges in the biopharmaceutical industry can impact the company's stock price and financial performance. Dependency on the success of key products like sacituzumab govitecan for revenue generation, which poses a risk if clinical trials do not meet expectations. Competition from other biopharmaceutical companies developing similar monoclonal antibody-based products may affect Immunomedics, Inc.'s market share and profitability. Investing in clinical-stage biopharmaceutical companies like Immunomedics, Inc. carries inherent risks due to uncertainties in drug development, regulatory approvals, and market acceptance. Fluctuations in the stock price of Immunomedics, Inc. can be influenced by factors such as market sentiment, industry trends, and macroeconomic conditions. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these Immunomedics pros and cons to contact@marketbeat.com. IMMU Stock Analysis - Frequently Asked Questions How were Immunomedics' earnings last quarter? Immunomedics, Inc. (NASDAQ:IMMU) announced its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.39. The biopharmaceutical company had revenue of $20.07 million for the quarter, compared to the consensus estimate of $24.81 million. What other stocks do shareholders of Immunomedics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Micron Technology (MU), NVIDIA (NVDA), Seagen (SGEN), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Intel (INTC). This page (NASDAQ:IMMU) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunomedics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.